Research progress on the role of sphingosine-1-phosphate in kidney diseases

doi:10.3877/cma.j.issn.2095-3216.2023.06.008

Abstract

Abstract:

Sphingolipids and sphingolipid metabolites are an important class of bioactive lipids, which are involved in signal transduction of various physiological and pathological processes such as cell growth and apoptosis. The expression changes of sphingolipids and sphingolipid metabolites in a variety of kidney diseases suggested that they may be involved in the development and progression of kidney diseases. Sphingosine-1-phosphate is an important bioactive sphingolipid metabolite, and can participate in the pathophysiological processes of acute kidney injury, diabetic kidney disease, and lupus nephritis, etc. Exploration of the regulation of sphingosine-1-phosphate metabolism and its signaling pathway may provide new ideas for the treatment of kidney diseases.

Key words: Sphingosine-1-phosphate, Kidney diseases, Sphingolipid metabolism

Xiayu Ren, Yanjuan Hou, Lihua Wang. Research progress on the role of sphingosine-1-phosphate in kidney diseases[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(06): 344-348.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2023.06.008

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2023/V12/I06/344

Figures/Tables 1

References 51

[1]	Hannun YA, Obeid LM. Sphingolipids and their metabolism in physiology and disease [J]. Nat Rev Mol Cell Biol, 2018, 19(3): 175-191.
[2]	Maceyka M, Harikumar KB, Milstien S, et al. Sphingosine-1-phosphate signaling and its role in disease [J]. Trends Cell Biol, 2011, 22(1): 50-60.
[3]	Ueda N. A rheostat of ceramide and sphingosine-1-phosphate as a determinant of oxidative stress-mediated kidney injury [J]. Int J Mol Sci, 2022, 23(7): 4010.
[4]	Drexler Y, Molina J, Mitrofanova A, et al. Sphingosine-1-phosphate metabolism and signaling in kidney diseases [J]. J Am Soc Nephrol, 2021, 32(1): 9-31.
[5]	Maceyka M, Spiegel S. Sphingolipid metabolites in inflammatory disease [J]. Nature, 2014, 510(7503): 58-67.
[6]	Yaghobian D, Don AS, Yaghobian S, et al. Increased sphingosine 1-phosphate mediates inflammation and fibrosis in tubular injury in diabetic nephropathy [J]. Clin Exp Pharmacol Physiol, 2016, 43(1): 56-66.
[7]	Mallela SK, Merscher S, Fornoni A. Implications of sphingolipid metabolites in kidney diseases [J]. Int J Mol Sci, 2022, 23(8): 4244.
[8]	Hait NC, Allegood J, Maceyka M, et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate [J]. Science, 2009, 325(5945): 1254-1257.
[9]	Alvarez SE, Harikumar KB, Hait NC, et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2 [J]. Nature, 2010, 465(7301): 1084-1088.
[10]	Hengst JA, Guilford JM, Fox TE, et al. Sphingosine kinase 1 localized to the plasma membrane lipid raft microdomain overcomes serum deprivation induced growth inhibition [J]. Arch Biochem Biophys, 2009, 492(1-2): 62-73.
[11]	Igarashi N, Okada T, Hayashi S, et al. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis [J]. J Biol Chem, 2003, 278(47): 46832-46839.
[12]	Reiss U, Oskouian B, Zhou J, et al. Sphingosine-phosphate lyase enhances stress-induced ceramide generation and apoptosis [J]. J Biol Chem, 2004, 279(2): 1281-1290.
[13]	Prasad R, Hadjidemetriou I, Maharaj A, et al. Sphingosine-1-phosphate lyase mutations cause primary adrenal insufficiency and steroid-resistant nephrotic syndrome [J]. J Clin Invest, 2017, 127(3): 942-953.
[14]	Mitra P, Oskeritzian CA, Payne SG, et al. Role of ABCC1 in export of sphingosine-1-phosphate from mast cells [J]. Proc Natl Acad Sci USA, 2006, 103(44): 16394-1639.
[15]	Tanfin Z, Serrano-Sanchez M, Leiber D. ATP-binding cassette ABCC1 is involved in the release of sphingosine 1-phosphate from rat uterine leiomyoma ELT3 cells and late pregnant rat myometriun [J]. Cell Signal, 2011, 23(12): 1997-2004.
[16]	Hisano Y, Kobayashi N, Yamaguchi A, et al. Mouse SPNS2 functions as a sphingosine-1-phosphate transporter in vascular endothelial cells [J]. PLoS One, 2012, 7(6): e38941.
[17]	Nijnik A, Clare S, Hale C, et al. The role of sphingosine-1-phosphate transporter Spns2 in immune system function [J]. J Immunol, 2012, 189(1): 102-111.
[18]	Vu TM, Ishizu AN, Foo JC, et al. Mfsd2b is essential for the sphingosine-1-phosphate export in erythrocytes and platelets [J]. Nature, 2017, 550(7677): 524-528.
[19]	Bisgaard LS, Christoffersen C. The ApoM/S1P complex-A mediator in kidney biology and disease? [J]. Front Med (Lausanne), 2021, 8: 754490.
[20]	Obinata H, Kuo A, Wada Y, et al. Identification of ApoA4 as a sphingosine-1-phosphate chaperone in ApoM- and albumin-deficient mice [J]. J Lipid Res, 2019, 60(11): 1912-1921.
[21]	Sun XJ, Wang C, Zhang LX, et al. Sphingosine-1-phosphate and its receptors in anti-neutrophil cytoplasmic antibody-associated vasculitis [J]. Nephrol Dial Transplant, 2017, 32(8): 1313-1322.
[22]	Awad AS, Rouse MD, Khutsishvili K, et al. Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes [J]. Kidney Int, 2011, 79(10): 1090-1098.
[23]	Ham A, Kim M, Kim JY, et al. Selective deletion of the endothelial sphingosine-1-phosphate 1 receptor exacerbates kidney ischemia-reperfusion injury [J]. Kidney Int, 2014, 85(4): 807-823.
[24]	Park SW, Kim M, Brown KM, et al. Inhibition of sphingosine-1-phosphate receptor 2 protects against renal ischemia-reperfusion injury [J]. J Am Soc Nephrol, 2012, 23(2): 266-280.
[25]	Asao R, Asanuma K, Kodama F, et al. Relationships between levels of urinary podocalyxin, number of urinary podocytes, and histologic injury in adult patients with IgA nephropathy [J]. Clin J Am Soc Nephrol, 2012, 7(9): 1385-1393.
[26]	Yoo TH, Pedigo CE, Guzman J, et al. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease [J]. J Am Soc Nephrol, 2015, 26(1): 133-147.
[27]	Ren S, Babelova A, Moreth K, et al. Transforming growth factor-beta2 upregulates sphingosine kinase-1 activity, which in turn attenuates the fibrotic response to TGF-beta2 by impeding CTGF expression [J]. Kidney Int, 2009, 76(8): 857-867.
[28]	Lan T, Liu W, Xie X, et al. Sphingosine kinase-1 pathway mediates high glucose-induced fibronectin expression in glomerular mesangial cells [J]. Mol Endocrinol, 2011, 25(12): 2094-2105.
[29]	Yaghobian D, Don AS, Yaghobian S, et al. Increased sphingosine-1-phosphate mediates inflammation and fibrosis in tubular injury in diabetic nephropathy [J]. Clin Exp Pharmacol Physiol, 2016, 43(1): 56-66.
[30]	Lan T, Shen X, Liu P, et al. Berberine ameliorates renal injury in diabetic C57BL/6 mice: involvement of suppression of SphK-S1P signaling pathway [J]. Arch Biochem Biophys, 2010, 502(2): 112-120.
[31]	Ahmad A, Mitrofanova A, Bielawski J, et al. Sphingomyelinase-like phosphodiesterase 3b mediates radiation-induced damage of renal podocytes [J]. FASEB J, 2017, 31(2): 771-780.
[32]	Azzam P, Francis M, Youssef T, et al. Crosstalk between SMPDL3b and NADPH oxidases mediates radiation-induced damage of renal podocytes [J]. Front Med (Lausanne), 2021, 8: 732528.
[33]	Rizk DV, Saha MK, Hall S, et al. Glomerular immunodeposits of patients with IgA nephropathy are enriched for IgG autoantibodies specific for galactose-deficient IgA1 [J]. J Am Soc Nephrol, 2019, 30(10): 2017-2026.
[34]	Kurano M, Tsuneyama K, Morimoto Y, et al. Apolipoprotein M suppresses the phenotypes of IgA nephropathy in hyper-IgA mice [J]. FASEB J, 2019, 33(4): 5181-5195.
[35]	Rin A, Katsuhiko A, Fumiko K, et al. Relationships between levels of urinary podocalyxin, number of urinary podocytes, and histologic injury in adult patients with IgA nephropathy [J]. Clin J Am Soc Nephrol, 2012, 7(9): 1385-1393.
[36]	Bensimhon AR, Williams AE, Gbadegesin RA. Treatment of steroid-resistant nephrotic syndrome in the genomic era [J]. Pediatr Nephrol, 2019, 34(11): 2279-2293.
[37]	Kemper MJ, Lemke A. Treatment of genetic forms of nephrotic syndrome [J]. Front Pediatr, 2018, 6: 72.
[38]	Lovric S, Goncalves S, Gee HY, et al. Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency [J]. J Clin Invest, 2017, 127(3): 912-928.
[39]	Patyna S, Büttner S, Eckes T, et al. Blood ceramides as novel markers for renal impairment in systemic lupus erythematosus [J]. Prostaglandins Other Lipid Mediat, 2019, 144: 106348.
[40]	Mohammed S, Vineetha NS, James S, et al. Examination of the role of sphingosine kinase 2 in a murine model of systemic lupus erythematosus [J]. FASEB J, 2019, 33(6): 7061-7071.
[41]	Okazaki H, Hirata D, Kamimura T, et al. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus [J]. J Rheumatol, 2002, 29(4): 707-716.
[42]	Alperovich G, Rama I, Lloberas N, et al. New immunosuppresor strategies in the treatment of murine lupus nephritis [J]. Lupus, 2007, 16(1): 18-24.
[43]	Taylor Meadows KR, Steinberg MW, Clemons B, et al. Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus [J]. PLoS One, 2018, 13(4): e0193236.
[44]	Sun XJ, Wang C, Zhang LX, et al. Sphingosine-1-phosphate and its receptors in anti-neutrophil cytoplasmic antibody-associated vasculitis [J]. Nephrol Dial Transplant, 2017, 32(8): 1313-1322.
[45]	Hao J, Huang YM, Zhao MH, et al. The interaction between C5a and sphingosine-1-phosphate in neutrophils for antineutrophil cytoplasmic antibody mediated activation [J]. Arthritis Res Ther, 2014, 16(4): R142.
[46]	Fornoni A, Sageshima J, Wei C, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis [J]. Sci Transl Med, 2011, 3(85): 85ra46.
[47]	di Meo NA, Lasorsa F, Rutigliano M, et al. Renal cell carcinoma as a metabolic disease: an update on main pathways, potential biomarkers, and therapeutic targets [J]. Int J Mol Sci, 2022, 23(22): 14360.
[48]	Stepanovska Tanturovska B, Manaila R, Fabbro D, et al. Lipids as targets for renal cell carcinoma therapy [J]. Int J Mol Sci, 2023, 24(4): 3272.
[49]	Suzuki S, Kakefuda T, Amemiya H, et al. An immunosuppressive regimen using FTY720 combined with cyclosporin in canine kidney transplantation [J]. Transpl Int, 1998, 11(2): 95-101.
[50]	Ueda H, Takahara S, Azuma H, et al. Effect of a novel immunosuppressant, FTY720, on allograft survival after renal transplant in rats [J]. Eur Surg Res, 2000, 32(5): 279-283.
[51]	Wang P, Yuan Y, Lin W, et al. Roles of sphingosine-1-phosphate signaling in cancer [J]. Cancer Cell Int, 2019, 19: 295.

Please choose a citation manager

Content to export